GSK to Inject $30 Billion into US R&D and Manufacturing Over the Next 5 Years

GSK plc (LON: GSK) announced a massive $30 billion investment in its United States operations over the next five years.

The commitment encompasses both research and development and critical supply chain infrastructure.

The headline figure includes an immediate $1.2 billion injection into advanced manufacturing facilities and AI-driven technologies.

The new facilities are strategically designed to bridge the gap between R&D and manufacturing processes across both the U.S. and the U.K.

This initial $1.2 billion will be allocated to several key areas. A new biologics “flex” factory will be constructed in Upper Merion, Pennsylvania, targeting the development of innovative medicines for respiratory diseases like COPD and asthma, as well as various cancers.

GSK also plans to integrate new AI and advanced digital technology capabilities across its existing five manufacturing sites located in Pennsylvania, North Carolina, Maryland, and Montana. The investment will also bolster drug substance manufacturing, device, and auto-injector capabilities.

The broader $30 billion investment will be spread across GSK's U.S. supply chain, increased R&D spending, and expanded clinical trial activity. The U.S. is projected to become GSK's leading hub for clinical studies, sites, and participant enrollment over the next five years.

Today’s announcement brings GSK’s new investments in U.S. manufacturing to approximately $2 billion over the last 12 months.

GSK’s commitment to the U.S. market is further underscored by the ongoing construction of an $800 million facility in Marietta, Pennsylvania, which commenced in October 2024. This expansion will effectively double the size and capacity of the existing site. These investments are expected to create hundreds of highly skilled jobs, adding to GSK's existing U.S. workforce of approximately 15,000 employees.

CEO Emma Walmsley stated, “Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country. $1.2 billion of today's announcement includes construction of an additional next-gen biologics “flex” factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”